Travere Therapeutics (TVTX) has provided an announcement.
During the Annual Meeting on May 8, 2024, stockholders of the company made key decisions affecting the future of the business. They elected ten directors to serve until the next annual meeting, approved an amendment to increase the number of shares for the Equity Incentive Plan, endorsed the executive officers’ compensation, and ratified Ernst & Young LLP as the independent accounting firm for the upcoming fiscal year. These outcomes, determined by the majority of votes, reflect shareholder support for the current management and strategic initiatives.
For a thorough assessment of TVTX stock, go to TipRanks’ Stock Analysis page.
